Eloralintide Obesity Treatment: Phase 2 Trial R...

By HEOR Staff Writer

November 7, 2025

Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy
Sanofi Insulin Savings: Your Comprehensive Guide for 2025
Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascul...
Insights on GLP-1 Therapy in Bariatric Surgery Patients
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Building a Better Ecosystem for Digitally Enabled Diabetes Care in Europe
Comprehensive Review of Type 2 Diabetes Treatment and Diagnosis Strategies
T1 Diabetes Care with an Implantable Glucose Device
Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share
Another GLP-1 Drug Access Model: Will a Co-Pay Cap Revolutionize Affordability?
Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron ...